Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
52-week range
$12.78 – $40.56
100% from low
Borrow rate
0.40%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $6.9M | $0 | $15.0M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $6.9M | $0 | $15.0M |
| Gross margin | — | — | — | — | 100.0% | — | 100.0% |
| R&D | $4.3M | $9.3M | $96.3M | $155.1M | $124.4M | $150.2M | $172.2M |
| Operating income | −$5.1M | −$10.4M | −$374.9M | −$212.3M | −$171.3M | −$201.1M | −$207.7M |
| EBITDA | −$5.0M | −$10.3M | −$139.3M | −$209.5M | −$165.4M | −$221.9M | −$183.3M |
| Net income | −$5.3M | −$10.7M | −$381.9M | −$216.2M | −$151.1M | −$235.8M | −$197.5M |
| Net margin | — | — | — | — | -2204.7% | — | -1316.9% |
| EPS (diluted) | -0.05 | -0.08 | -4.24 | -2.31 | -1.57 | -2.06 | -1.46 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-1.64 | $-1.81–$-1.59 | 2 |
| 2027 | $25M | $-1.70 | $-1.92–$-1.56 | 6 |
| 2028 | $220M | $-1.12 | $-2.38–$1.29 | 9 |
| 2029 | $496M | $0.81 | $0.81–$0.81 | 3 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds CNTA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 164,600 | $4.0M |
No one on the platform has traded CNTA yet.
| $6.4B |
| — |
| DYNDyne Therapeutics, Inc. | $22.62 | +6.40% | $3.7B | — |
| LEGNLegend Biotech Corporation | $28.93 | -1.55% | $5.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CNTA Equity Corporate Actions Alert #2026 - 416 Information Regarding the Merger of Centessa Pharmaceuticals plc (CNTA) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-416 At a special meeting held on June 12, 2026, the shareholders of Centessa Pharmaceuticals plc (CNTA) approved the proposed merger with Eli Lilly and Company. The merger is tentatively scheduled to close prior to the market open on June 24, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on June 23, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (June 24th) and will be suspended effective June 25, 2026.
View on StockTwits ↗THINGS TO WATCH, FRIDAY, 6/12/2026 👁️ $SPCX.X $LLY $CNTA $KLAC $SPY
View on StockTwits ↗RECAP 4/29 Unusual Puts: $CNTA Jul 35 P $BMNR Jun 15 P $ONDS Dec 6 P $CCJ May29 85 P $ONDS Jun 8 P $WMT May01 125 P Live Breaking trading news www.openoutcrier.com
View on StockTwits ↗Eli Lilly’s Been On An Acquisition Spree This Year – Here’s A Look At Its Major Deals $LLY $CNTA https://stocktwits.com/news/equity/markets/eli-lilly-acquisition-spree-this-year-look-at-its-major-deals/cZBNxaDRePo
View on StockTwits ↗$CNTA Centessa downgraded to Hold from Buy at Truist Truist analyst Danielle Brill downgraded Centessa (CNTA) to Hold from Buy with a $38 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable contingent value right worth up to $9 per share.
View on StockTwits ↗$CNTA Price: $39.67 (-0.46%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±6.06% RSI: 78.5 | Momentum: Strong Momentum Volume: -60.0% vs avg Volatility: 10.45% Support: $25.06 | Resistance: $40.26 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
View on StockTwits ↗KALV / PHVS potential big pharma acquisitions for hereditary angioedema (HAE) treatments. $APLS $DAWN $FOLD $EXAS $CNTA . BEP energy play.
View on StockTwits ↗$CNTA Stock analysis https://youtu.be/DKJlY-cIfwo?si=d8brZd4Aq_Muj25T
View on StockTwits ↗$LLY just made a $7.8B move — and it’s not about obesity 👀 Lilly is acquiring $CNTA for $6.3B upfront (up to $7.8B with CVRs), adding a pipeline of OX2R agonists led by cleminorexton in mid-stage trials for narcolepsy and IH — a clear push to diversify beyond its GLP-1 dominance 💊 Centessa stock surged 44% on the news, while Lilly gained ~4%, signaling strong market approval of the strategy. Latest LLY news here 👉 https://www.zacks.com/stock/quote/LLY?cid=sm-stocktwits-0-quote_overview-oc-37620&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_37620
View on StockTwits ↗🚀 Bulls in full charge today! 🐂🔥 Huge congrats to everyone riding these top movers on March 31: $FLY +20% – Space stocks lifting off on SpaceX IPO buzz and sector momentum! $APLS +135% – Biogen acquiring Apellis for $5.6B in a blockbuster immunology deal! $CNTA +44% – Eli Lilly snapping up Centessa for up to $7.8B to boost sleep-wake disorder pipeline! Epic green day – keep stacking those gains, bulls! 💪📈 Who else is celebrating? #TopMovers #BullMarket #Stocks
View on StockTwits ↗Top Gainers PT2 $KIDZ $GVH $WSHP $CNTA $HKIT
View on StockTwits ↗Eli Lilly Just Made a $7 Billion Bet on the Future of Sleep: https://www.smartinvestornews.com/all-articles/eli-lilly-just-made-a-7-billion-bet-on-the-future-of-sleep $LLY $CNTA
View on StockTwits ↗52 week highs breakout stocks $APLS $CNTA $UNIT $BTE $PFE breakouts show selective accumulation RSI elevated yet volume confirms institutions adding not distributing
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.